Abstract
Platelets from patients affected by diabetes mellitus and metabolic syndrome show an impaired sensitivity to physiological antiaggregating agents and an enhanced activation state, mirrored by an increased expression of membrane activation markers; furthermore, they are more prone to form spontaneous microaggregates with ADP receptor involvement. These abnormalities are responsible for a pro-thrombotic condition, contributing to a high cardiovascular risk. This pattern of platelet abnormalities provides a strong rationale for aggressive antiplatelet therapy strongly recommended by guidelines both in diabetes mellitus and in metabolic syndrome, not only in the setting of acute coronary syndromes, but also for the long-term prevention of the cardiovascular events. Antiplatelet therapy in these pathological conditions, however, is still a matter of intense debate, especially because a high prevalence of “resistance” to these drugs (and to aspirin in particular) has been described in these patients. This may result in non-significant reductions in cardiovascular events. Different factors seem to be involved, including: i) genetic polymorphisms; ii) hyperglycemia and poor metabolic control; iii) reduced sensitivity to nitric oxide; iv) a pro-inflammatory and/or pro-thrombotic status, and, v) increased oxidative stress. This review will take into consideration: i) the results of the most relevant studies addressing the effects of the antiaggregating treatment in patients affected by diabetes mellitus and/or metabolic syndrome, and, ii) the biochemical mechanisms accounting for the impaired sensitivity to aspirin and thienopyridines in the above mentioned clinical conditions.
Keywords: Aspirin, cardiovascular disease, clopidogrel, metabolic syndrome, nitric oxide, obesity, platelets, thienopyridines, ticlopidine, type 2 diabetes mellitus
Current Vascular Pharmacology
Title: Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome
Volume: 6 Issue: 4
Author(s): Giovanni Anfossi, Isabella Russo and Mariella Trovati
Affiliation:
Keywords: Aspirin, cardiovascular disease, clopidogrel, metabolic syndrome, nitric oxide, obesity, platelets, thienopyridines, ticlopidine, type 2 diabetes mellitus
Abstract: Platelets from patients affected by diabetes mellitus and metabolic syndrome show an impaired sensitivity to physiological antiaggregating agents and an enhanced activation state, mirrored by an increased expression of membrane activation markers; furthermore, they are more prone to form spontaneous microaggregates with ADP receptor involvement. These abnormalities are responsible for a pro-thrombotic condition, contributing to a high cardiovascular risk. This pattern of platelet abnormalities provides a strong rationale for aggressive antiplatelet therapy strongly recommended by guidelines both in diabetes mellitus and in metabolic syndrome, not only in the setting of acute coronary syndromes, but also for the long-term prevention of the cardiovascular events. Antiplatelet therapy in these pathological conditions, however, is still a matter of intense debate, especially because a high prevalence of “resistance” to these drugs (and to aspirin in particular) has been described in these patients. This may result in non-significant reductions in cardiovascular events. Different factors seem to be involved, including: i) genetic polymorphisms; ii) hyperglycemia and poor metabolic control; iii) reduced sensitivity to nitric oxide; iv) a pro-inflammatory and/or pro-thrombotic status, and, v) increased oxidative stress. This review will take into consideration: i) the results of the most relevant studies addressing the effects of the antiaggregating treatment in patients affected by diabetes mellitus and/or metabolic syndrome, and, ii) the biochemical mechanisms accounting for the impaired sensitivity to aspirin and thienopyridines in the above mentioned clinical conditions.
Export Options
About this article
Cite this article as:
Anfossi Giovanni, Russo Isabella and Trovati Mariella, Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome, Current Vascular Pharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157016108785909760
DOI https://dx.doi.org/10.2174/157016108785909760 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Moringa oleifera on Insulin Levels and Folliculogenesis in Polycystic Ovary Syndrome Model with Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Serum Pro-oxidant-antioxidant Balance in Subjects with Type 2 Diabetes Mellitus
Combinatorial Chemistry & High Throughput Screening Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design Heart Failure in North America
Current Cardiology Reviews La(NO<sub>3</sub>)<sub>3</sub>.6H<sub>2</sub>O Catalyzed One-pot Highly Diastereoselective Synthesis of Functionalized Piperidines
Letters in Organic Chemistry Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance
Current Pharmaceutical Design The Adipose Tissue in Farm Animals: A Proteomic Approach
Current Protein & Peptide Science The Significance of Oxidized Low-Density Lipoprotein in Body Fluids as a Marker Related to Diseased Conditions
Current Medicinal Chemistry HIV-Therapy Associated Lipodystrophy: Experimental and Clinical Evidence for the Pathogenesis and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood-Based Biomarkers of Alzheimer´s Disease: Diagnostic Algorithms and New Technologies
Current Alzheimer Research Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020)
Current Medicinal Chemistry Chronic Pancreatitis and the Development of Pancreatic Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design The Role of the Endoplasmic Reticulum in the Accumulation of β-Amyloid Peptide in Alzheimers Disease
Current Molecular Medicine Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Pharmacological Treatment of Nonalcoholic Fatty Liver
Current Medicinal Chemistry Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Novel Therapeutic Targets for Management of Type-2 Diabetes Mellitus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)